First human test of Dual-Attack cancer therapy begins
NCT ID NCT06946225
Summary
This is a first-in-human study to test the safety and early effectiveness of a two-part treatment called IMA203 combined with mRNA-4203. It is for people with advanced skin cancer (melanoma) or a rare soft-tissue cancer (synovial sarcoma) that has spread and no longer responds to standard treatments. The main goal is to find a safe dose and see if the treatment can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Email: •••••@•••••
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.